Shares of Iqvia Holdings Inc (NYSE:IQV) have been given an average recommendation of “Buy” by the twenty research firms that are currently covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $106.06.

A number of analysts recently commented on the company. KeyCorp reaffirmed a “buy” rating and set a $100.00 price objective on shares of Iqvia in a research note on Sunday, September 24th. Robert W. Baird reaffirmed a “hold” rating and set a $98.00 price objective on shares of Iqvia in a research note on Monday, October 9th. Zacks Investment Research lowered Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Royal Bank of Canada assumed coverage on Iqvia in a research note on Tuesday, September 19th. They set an “outperform” rating and a $116.00 price objective on the stock. Finally, Argus increased their price objective on Iqvia from $98.00 to $104.00 and gave the company a “buy” rating in a research note on Monday, September 18th.

In related news, Director Jack M. Greenberg sold 33,400 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $108.07, for a total transaction of $3,609,538.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ari Bousbib sold 46,080 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $108.14, for a total value of $4,983,091.20. Following the transaction, the insider now owns 1,036,839 shares in the company, valued at $112,123,769.46. The disclosure for this sale can be found here. Insiders have sold 8,806,558 shares of company stock worth $898,722,108 over the last quarter. 6.40% of the stock is currently owned by company insiders.

Iqvia (IQV) traded up $1.28 during trading on Monday, reaching $98.56. The company’s stock had a trading volume of 1,381,600 shares, compared to its average volume of 1,316,150. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.22 and a quick ratio of 1.22. The firm has a market capitalization of $20,499.29, a price-to-earnings ratio of 339.87, a price-to-earnings-growth ratio of 1.36 and a beta of 0.61. Iqvia has a 12 month low of $74.80 and a 12 month high of $110.67.

Iqvia (NYSE:IQV) last posted its earnings results on Thursday, October 26th. The medical research company reported $1.19 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.14 by $0.05. The company had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. Iqvia’s revenue was up 77.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.00 earnings per share. equities research analysts anticipate that Iqvia will post 4.62 earnings per share for the current fiscal year.

WARNING: This report was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at

Iqvia Company Profile

IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with Analyst Ratings Network's FREE daily email newsletter.